Immix Biopharma, Inc. IMMX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $20.26M+24.6% | $16.26M+36.6% | $11.91M+1.2% | $11.77M+17.4% | $10.02M-11.3% | ||
| $15.81M+15.4% | $13.7M+12.8% | $12.14M+1.1% | $12.02M+2.3% | $11.75M+3.2% | ||
| $36.08M+20.4% | $29.96M+24.6% | $24.05M+1.1% | $23.78M+9.3% | $21.77M-4.0% | ||
| $36.08M+20.4% | $29.96M+24.6% | $24.05M+1.1% | $23.78M+9.3% | $21.77M-4.0% | ||
| -$36.08M-20.4% | -$29.96M-24.6% | -$24.05M-1.1% | -$23.78M-9.3% | -$21.77M+4.0% | ||
| $1.12M+102% | $555.53K+5.9% | $524.67K-24.7% | $696.81K-22.5% | $899.67K-11.6% | ||
| $1.12M+102% | $555.53K+5.9% | $524.67K-24.7% | $696.81K-22.5% | $899.67K-11.6% | ||
| -$34.95M-18.9% | -$29.4M-25.0% | -$23.53M-1.9% | -$23.09M-10.6% | -$20.87M+3.6% | ||
| —— | $37.72K+1.3% | $37.24K-8.4% | $40.67K-3.2% | $42.02K+2.4% | ||
| -$34.94M-18.9% | -$29.4M-24.8% | -$23.56M-1.9% | -$23.13M-10.7% | -$20.9M+3.3% | ||
| -$0.92-3.4% | -$0.89-15.6% | -$0.770.0% | -$0.77-10.0% | -$0.70+9.1% | ||
| -$0.92-3.4% | -$0.89-15.6% | -$0.770.0% | -$0.77-10.0% | -$0.70+9.1% | ||
| 150.2M+20.6% | 124.6M+3.9% | 119.9M+2.1% | 117.4M+1.0% | 116.2M+5.7% | ||
| 150.2M+20.6% | 124.6M+3.9% | 119.9M+2.1% | 117.4M+1.0% | 116.2M+5.7% | ||
| —— | —— | —— | —— | —— | ||
| $23.34K-63.3% | $63.52K+149% | -$129.59K-149% | -$51.94K+30.0% | -$74.15K+45.4% | ||
| -$36.08M-20.4% | -$29.96M-24.6% | -$24.05M-1.1% | -$23.78M-9.3% | -$21.77M+4.0% | ||
| -$35.78M-20.4% | -$29.71M-24.6% | -$23.84M-0.7% | -$23.66M-9.0% | -$21.7M+4.2% | ||
| -$35.78M-20.4% | -$29.71M-24.6% | -$23.84M-0.7% | -$23.66M-9.0% | -$21.7M+4.2% | ||
| -$36.08M-20.4% | -$29.96M-24.6% | -$24.05M-1.1% | -$23.78M-9.3% | -$21.77M+4.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Immix Biopharma, Inc. profitable?
- Immix Biopharma, Inc. is not currently profitable: it reported a net loss of $34.9M over the trailing twelve months.
- What is Immix Biopharma, Inc.'s earnings per share?
- Immix Biopharma, Inc.'s diluted EPS over the trailing twelve months is $-0.92.
- Where does Immix Biopharma, Inc.'s income statement data come from?
- Every line is extracted from Immix Biopharma, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.